Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | PDE1A | P54750 | 1/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4539823 | 0.82 | NPC1 (0.40) | NPC1TSHRRAB9AACHESMN1; SMN2 | |
| SCHEMBL4536226 | 0.74 | SCN7A (0.58) | NPC1TSHRRAB9ASMN1; SMN2TDP1 | |
| SCHEMBL4541853 | 0.73 | SCN7A (0.44) | NPC1TSHRRAB9ALTA4H | |
| SCHEMBL2324209 | 0.70 | LTA4H (0.61) | TSHRSMN1; SMN2TDP1KDM4EALDH1A1 | |
| SCHEMBL4477326 | 0.69 | LTA4H (0.62) | ACHESMN1; SMN2TDP1KDM4ELTA4H | |
| SCHEMBL6657644 | 0.68 | MEN1 (0.45) | ACHEESR1LTA4H | |
| SCHEMBL4517043 | 0.68 | PSMB1 (0.67) | KDM4EESR1PDE1APDE1BPDE1C | |
| SCHEMBL4524330 | 0.68 | SMN1; SMN2 (0.49) | TSHRSMN1; SMN2TDP1KDM4ELTA4H | |
| SCHEMBL4465080 | 0.68 | SMN1; SMN2 (0.52) | TSHRSMN1; SMN2TDP1KDM4EALDH1A1 | |
| SCHEMBL4537398 | 0.68 | SCN7A (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | MSD K.K. (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1939194-A1 | BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | PYCR1, CHRM1, MTR | NPC1 3130/4885TSHR 1381/4885RAB9A 4390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.